1. Thiele J, Kvasnicka HM, Orazi A i wsp. Primary myelofibrosis. Swerdlow SH i wsp. (red.)., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC, Lyon 2017; 44-50.
2.
Thiele J, Kvasnicka HM, Mullauer L i wsp. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117: 5710-5718.
3.
Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 2014; 27: 129-140.
4.
Vannucchi AM, Lasho TL, Guglielmelli P i wsp. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
5.
Tefferi A, Lasho TL, Finke CM i wsp. Targeted deep sequencing in primary myelofibrosis. Blood Adv 2016; 1: 105-111.
6.
Tefferi A, Guglielmelli P, Nicolosi M i wsp. GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis. Leukemia 2018; 32: 1631-1642.
7.
Tefferi A. Primary Myelofibrosis: 2019 Update on Diagnosis, Risk-Stratification and Management Am J Hematol 2018; 93: 1551-1560.
8.
Zahr AA, Salama ME, Carreau N i wsp. Bone Marrow Fibrosis in Myelofibrosis: Pathogenesis, Prognosis and Targeted Strategies. Haematologica 2016; 101: 660-671.
9.
Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013; 24: 133-145.
10.
Hermouet S. Pathogenesis of myeloproliferative neoplasms: more than mutations. Exp Hematol 2015; 43: 993-994.
11.
Pardanani A, Lasho TL, Finke C i wsp. Extending JAK2V617F and MPL W515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007, 25: 2358-2362.
12.
Martyre MC, Le Bousse-Kerdiles MC, Romquin N i wsp. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997; 97: 441-448.
13.
Kuter DJ, Bain B, Mufti G i wsp. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139: 351-362.
14.
Ho CL, Lasho TL, Butterfield JH i wsp. Global cytokine analysis in myeloproliferative disorders. Leuk Res 2007; 31: 1389-1392.
15.
Tefferi A. Primary myelofibrosis and its paraneoplastic stromal effects. Haematologica 2007; 92: 577-579.
16.
Moulard O, Mehta J, Fryzek J i wsp. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 2014; 92: 289-297.
17.
Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl
18.
J Med 2000; 342: 1255-1265
19.
Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 915-925.
20.
Thiele J, Kvasnicka HM, Boeltken B i wsp. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) – a clinicopathological study. Leukemia 1999; 13: 1741-1748.
21.
Gisslinger H, Jeryczynski G, Gisslinger B i wsp. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 2016; 30: 1126-1132.
22.
Finazzi G, Carobbio A, Thiele J i wsp. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-719.
23.
Tefferi A, Mudireddy M, Mannelli F i wsp. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 2018; 32: 1200-1210.
24.
Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
25.
Boiocchi L, Espinal-Witter R, Geyer JT i wsp. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol 2013; 26: 204-212.
26.
Prochorec-Sobieszek M. Klasyfikacja i kryteria diagnostyczne nowotworów uk³adu krwiotwórczego. W: Wytyczne postêpowania diagnostyczno-leczniczego w nowotworach z³oœliwych w 2020 roku. Warzocha K (red.). Onkol Praktyce Klin 2020; 6 (supl. A): 19-38.
27.
Kvasnicka HM, Beham-Schmid Ch, Bob R i wsp. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. Histopathology 2016; 68: 905-915.
28.
Hematopathology. Jaffe ES, Harris NL, Vardiman JW i wsp. (eds.). Elsevier, St. Louis, MO 2011.
29.
Prochorec-Sobieszek M, Jesionek-Kupnicka D, Rymkiewicz G. Nowotwory uk³adu ch³onnego i krwiotwórczego. Pol J Pathol 2015; 66 (Supl. 1): 68-74.
30.
Tefferi A, Mudireddy M, Mannelli F i wsp. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 2018; 32: 1200-1210.
31.
Mudireddy M, Shah S, Lasho T i wsp. Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. Br J Haematol 2018; 182: 594-597.
32.
Nangalia J, Massie CE, Baxter EJ i wsp. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
33.
Tefferi A, Lasho TL, Finke CM i wsp. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
34.
Tefferi A, Lasho TL, Tischer A i wsp. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014; 124: 2465-2466.
35.
Andrikovics H, Krahling T, Balassa K i wsp. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 2014; 99: 1184-1190.
36.
Loscocco G, Guglielmelli P, Vannucchi A. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data. OncoTargets and Therapy 2020; 13: 12367-12382.
37.
Guglielmelli P, Lasho TL, Rotunno G i wsp. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810.
38.
Tefferi A, Finke CM, Lasho TL i wsp. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia 2018; 32: 2274-2278.
39.
Wassie E, Finke C, Gangat N i wsp. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol 2015; 169: 71-76.
40.
Tefferi A., Nicolosi M, Mudireddy M i wsp. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia 2018; 32: 1189-1199.
41.
Prakash S, Hoffman R, Barouk S i wsp. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol 2012; 25: 815-827.
42.
Thiele J, Kvasnicka HM, C Czieslick C. CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue. Ann Hematol 2002, 81: 86-89.
43.
Arber DA, Orazi A, Hasserjian R i wsp. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405.
44.
Guglielmelli P, Pacilli A, Rotunno G i wsp. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 2017; 129: 3227-3236.
45.
Barbui T, Barosi G, Birgegard G i wsp. Philadelphia-negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European Leukemia Net. J Clin Oncol 2011; 29: 761-770.
46.
Chou JM, Li C, Tefferi A i wsp. Bone Marrow Immunohistochemical Studies of Angiogenic Cytokines and Their Receptors in Myelofibrosis With Myeloid Metaplasia. Leuk Res 2003; 27: 499-504.
47.
Barosi G, Mesa RA, Thiele J i wsp. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
48.
Thiele J, Fischer R. Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview. Virchows Arch A Pathol Anat Histopathol 1991; 418: 87-97.
49.
Thiele J, Kvasnicka H, Orazi A i wsp. Polycythemia vera. Swerdlow SH i wsp. (red.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC, Lyon 2017; 39-43.
50.
Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; 27: 1953-1958.
51.
Thiele J, Kvasnicka H, Orazi A i wsp. Essential thrombocythaemia. Swerdlow SH i wsp. (red.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC, Lyon 2017; 50-53.
52.
Barbui T, Thiele J, Passamonti F i wsp. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
53.
52. Patnaik MM, Tefferi A. Refractory anemia with ring sidero53. blasts and RARS with thrombocytosis. Am J Hematol 2015, 90: 549-559.
54.
Sangle N, Cook J, Perkins S i wsp. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem Mol Morphol 2014; 22: 663-668.
55.
Orazi A, O’Malley DP, Jiang J i wsp. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005; 18: 603-614.
56.
Steensma DP, Hanson CA, Letendre L i wsp. Myelodysplasia with fibrosis: a distinct entity? Leuk Res 2001, 25: 829-838.
57.
Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol 2016; 91: 76-89.
58.
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol 2016; 91: 631-642.
59.
Vergara-Lluri ME, Pi¹tek CI, Pullarkat C i wsp. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol 2014; 45: 2183-2191.
60.
Cervantes F, Dupriez B, Pereira A i wsp. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 2009; 113: 2895-2901.
61.
Passamonti F, Cervantes F, Vannucchi AM i wsp. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
62.
Gangat N, Caramazza D, Vaidya R i wsp. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
63.
Guglielmelli P, Lasho TL, Rotunno G i wsp. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
64.
J Clin Oncol 2018; 36: 310-318.
65.
Tefferi A, Guglielmelli P, Lasho TL i wsp. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 2018; 36: 1769-1770.
66.
Passamonti F, Giorgino T, Mora B i wsp. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017; 31: 2726-2731.
